In the News
Welcome to our news archive, your resource for company announcements, press releases, and media coverage. Here you’ll find updates on our latest initiatives, strategic partnerships, and industry contributions, as well as background materials to support media inquiries. Explore past stories to see how we continue to shape conversations across healthcare and life sciences.
For this article on GLP-1 market dynamics, Investor’s Business Daily reached out to MMIT CCO Jayne Hornung for her insights on pricing, affordability, and whether the oral version of these drugs will reach a previously untapped market.
For this investigative article about the origins, operations and impact of alternative funding programs (AFPs), Fierce Healthcare asked MMIT to provide a custom survey of payers and PBMs. Most are concerned about the legality of AFPs, an opinion shared by manufacturers, many of which prohibit patients with an AFP from applying to their patient support programs.
PharmaVoice reached out to MMIT’s Alicia Heesen for insights into how Merck’s release of the subcutaneous agent Keytruda Qlex will extend its market share and increase potential revenue. Alicia shares payer preferences for faster, less expensive, and more convenient treatment options.
Forbes reached out to MMIT CCO Jayne Hornung in the wake of the recent announcement for TrumpRx, an impending website set to join the slew of direct-to-consumer offerings for prescription drugs. Jayne weighed in on the potential scope, coverage and impact of the new site.
MMIT CCO Jayne Hornung participated in a TechTarget/Xtelligent Healthcare panel on the expansion of GLP-1s into new indications. Jayne explained how payers influence pharma companies’ prioritization of the indications in their pipelines, and discussed the importance of finding the link between inflammation and gut-brain signaling.
MMIT’s CCO, Jayne Hornung, talks to IBD about Wegovy’s recent approval to treat patients with MASH, an underdiagnosed, advanced form of fatty liver disease. She discusses how this approval could drive increased diagnoses, impact Rezdiffra usage, and unlock a large new market for Novo Nordisk.